Home › Compare › TRGNF vs NNN

TRGNF vs NNN: Dividend Comparison 2026

TRGNF yields 200.00% · NNN yields 5.68%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TRGNF wins by $119.34M in total portfolio value
10 years
TRGNF
TRGNF
● Live price
200.00%
Share price
$1.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$119.36M
Annual income
$60,176,096.29
Full TRGNF calculator →
NNN
NNN REIT Inc.
● Live price
5.68%
Share price
$41.89
Annual div
$2.38
5Y div CAGR
8.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.6K
Annual income
$2,637.42
Full NNN calculator →

Portfolio growth — TRGNF vs NNN

📍 TRGNF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTRGNFNNN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TRGNF + NNN cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
TRGNF pays
NNN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TRGNF
Annual income on $10K today (after 15% tax)
$17,000.00/yr
After 10yr DRIP, annual income (after tax)
$51,149,681.85/yr
NNN
Annual income on $10K today (after 15% tax)
$482.93/yr
After 10yr DRIP, annual income (after tax)
$2,241.81/yr
At 15% tax rate, TRGNF beats the other by $51,147,440.04/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TRGNF + NNN for your $10,000?

TRGNF: 50%NNN: 50%
100% NNN50/50100% TRGNF
Portfolio after 10yr
$59.69M
Annual income
$30,089,366.85/yr
Blended yield
50.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on NNN right now

TRGNF
No analyst data
Altman Z
2.5
Piotroski
3/9
NNN
Analyst Ratings
10
Buy
15
Hold
4
Sell
Consensus: Hold
Price Target
$44.93
+7.3% upside vs current
Range: $43.00 — $48.50
Altman Z
1.1
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TRGNF buys
0
NNN buys
0
No recent congressional trades found for TRGNF or NNN in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTRGNFNNN
Forward yield200.00% ✓5.68%
Annual dividend / share$2.00$2.38 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%8.6% ✓
Portfolio after 10y$119.36M ✓$25.6K
Annual income after 10y$60,176,096.29 ✓$2,637.42
Total dividends collected$112.49M ✓$13.7K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: TRGNF vs NNN ($10,000, DRIP)

YearTRGNF PortfolioTRGNF Income/yrNNN PortfolioNNN Income/yrGap
1← crossover$30,700$20,000.00$10,737$617.02+$20.0K → TRGNF
2$90,232$57,383.18$11,577$710.93+$78.7K → TRGNF
3$254,173$157,624.56$12,538$822.59+$241.6K → TRGNF
4$686,927$414,961.74$13,645$956.06+$673.3K → TRGNF
5$1,783,118$1,048,106.39$14,925$1,116.51+$1.77M → TRGNF
6$4,450,613$2,542,677.12$16,415$1,310.57+$4.43M → TRGNF
7$10,693,420$5,931,263.38$18,158$1,546.77+$10.68M → TRGNF
8$24,760,608$13,318,648.86$20,213$1,836.20+$24.74M → TRGNF
9$55,315,649$28,821,798.66$22,649$2,193.37+$55.29M → TRGNF
10$119,363,841$60,176,096.29$25,558$2,637.42+$119.34M → TRGNF

TRGNF vs NNN: Complete Analysis 2026

TRGNF — Stock

Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors. It has strategic collaboration agreements with AstraZeneca, Merck KGaA, Pfizer, PersonGen BioTherapeutics, and NEC Corporation; licensing agreements with SillaJen, Ascend BioPharmaceutical, and Valneva; and agreements with Sanofi, BioInvent, and Randox. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

Full TRGNF Calculator →

NNN — REIT

National Retail Properties invests primarily in high-quality retail properties subject generally to long-term, net leases. As of September 30, 2020, the company owned 3,114 properties in 48 states with a gross leasable area of approximately 32.4 million square feet and with a weighted average remaining lease term of 10.7 years.

Full NNN Calculator →
📬

Get this TRGNF vs NNN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TRGNF vs SCHDTRGNF vs JEPITRGNF vs OTRGNF vs KOTRGNF vs MAINTRGNF vs ADCTRGNF vs EPRTTRGNF vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.